Umbellatine
Abdominal Obesity-Metabolic Syndrome
Nanjing First Hospital, Nanjing Medical UniversitySmall moleculePhase 4 / ApprovedActive
BB
69/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 67/ 100
- Competitive Position
- 73/ 100
Competitive context
41 Active assets in the Abdominal Obesity-Metabolic Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Topiramate All India Institute of Medical Sciences, Bhubaneswar | Phase 4 | BBB |
Atorvastatin Seoul National University Hospital | Phase 4 | BBB |
Pioglitazone Philip Kern | Phase 4 | BBB |
Rosuvastatin Hamdard University | Phase 4 | BBB |
Olmesartan Medoxomil Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
Umbellatine is also rated in:
metabolic dysfunction-associated steatotic liver diseaseActive
BB
Indicative · Phase 4
69 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →